Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
作者信息
Barbanti Piero, Egeo Gabriella, Aurilia Cinzia, d'Onofrio Florindo, Albanese Maria, Cetta Ilaria, Di Fiore Paola, Zucco Maurizio, Filippi Massimo, Bono Francesco, Altamura Claudia, Proietti Stefania, Bonassi Stefano, Vernieri Fabrizio
机构信息
Headache and Pain Unit, IRCCS San Rafaele Pisana, Rome, Italy.
San Rafaele University, Rome, Italy.
出版信息
J Headache Pain. 2022 Apr 28;23(1):51. doi: 10.1186/s10194-022-01422-y.
Abstract
摘要
相似文献
1
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).对《Fremanezumab预防高频发作性和慢性偏头痛：一项为期12周的多中心、真实生活队列研究（FRIEND研究）》的勘误
J Headache Pain. 2022 Apr 28;23(1):51. doi: 10.1186/s10194-022-01422-y.
2
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).依利格鲁司他治疗早发型家族性阿尔茨海默病的有效性和安全性：一项随机、双盲、安慰剂对照的 3 期临床试验（EMERGE 研究）
J Headache Pain. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x.
3
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).更正：fremanezumab预防高频发作性和慢性偏头痛：一项为期12周的多中心、真实生活队列研究（FRIEND研究）
J Headache Pain. 2022 Jun 7;23(1):64. doi: 10.1186/s10194-022-01434-8.
4
PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine.PEARL 研究方案：一项评估 fremanezumab 治疗慢性或阵发性偏头痛患者有效性的真实世界研究。
Pain Manag. 2021 Nov;11(6):647-654. doi: 10.2217/pmt-2021-0015. Epub 2021 Jun 9.
5
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.在高频发作性偏头痛的随机 2 期研究中，用佛来美尼单抗起始治疗对头痛及相关症状的影响：治疗最初 3 周的事后分析。
Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.
6
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.氟雷马尼单抗对比安慰剂用于预防阵发性偏头痛的疗效：一项随机临床试验。
JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.
7
Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.氟来米特钠治疗偏头痛预防的长期安全性和耐受性：一项多中心、随机、开放标签研究。
Drug Saf. 2021 Dec;44(12):1355-1364. doi: 10.1007/s40264-021-01119-2. Epub 2021 Oct 23.
8
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.用于预防偏头痛的依瑞奈珠单抗的安全性和耐受性：2b 期和 3 期临床试验的汇总分析。
Headache. 2019 Jun;59(6):880-890. doi: 10.1111/head.13534. Epub 2019 Apr 12.
9
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.在美国患有发作性和慢性偏头痛或难治性偏头痛的患者中开始使用依洛尤单抗治疗后的真实世界疗效。
J Headache Pain. 2022 May 16;23(1):56. doi: 10.1186/s10194-022-01415-x.
10
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.季度或月度给药频次下无氟麦角隐亭出现“时效减退”现象：一项随机长期研究的亚组分析。
Headache. 2020 Nov;60(10):2431-2443. doi: 10.1111/head.13994. Epub 2020 Oct 28.
引用本文的文献
1
Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium.重新审视偏头痛：不断演变的病理生理学与不断扩充的治疗手段
Cureus. 2023 Feb 2;15(2):e34553. doi: 10.7759/cureus.34553. eCollection 2023 Feb.
本文引用的文献
1
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).依利格鲁司他治疗早发型家族性阿尔茨海默病的有效性和安全性：一项随机、双盲、安慰剂对照的 3 期临床试验（EMERGE 研究）
J Headache Pain. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x.
Zotero 插件